# Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

> **NCT02014649** · PHASE1,PHASE2 · TERMINATED · sponsor: **Biota Scientific Management Pty Ltd** · enrollment: 15 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** 20 mg laninamivir octanoate
- **DRUG:** Placebo
- **DRUG:** 40 mg laninamivir octanoate

## Key facts

- **NCT ID:** NCT02014649
- **Lead sponsor:** Biota Scientific Management Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2014-04
- **Final completion:** 2014-05
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study was terminated as per BARDA decision to terminate contract.
- **Last updated:** 2025-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014649, "Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02014649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*